

SCIENTIFIC REPORTS



OPEN

Altered brain metabolic connectivity at multiscale level in early Parkinson's disease

Arianna Sala^{1,2}, Silvia Paola Caminiti^{1,2}, Luca Presotto², Enrico Premi³, Andrea Pilotto^{3,4}, Rosanna Turrone³, Maura Cosseddu³, Antonella Alberici³, Barbara Paghera⁵, Barbara Borroni³, Alessandro Padovani³ & Daniela Perani^{1,2,6}

To explore the effects of PD pathology on brain connectivity, we characterized with an emergent computational approach the brain metabolic connectome using [18F]FDG-PET in early idiopathic PD patients. We applied whole-brain and pathology-based connectivity analyses, using sparse-inverse covariance estimation in thirty-four cognitively normal PD cases and thirty-four age-matched healthy subjects for comparisons. Further, we assessed high-order resting state networks by interregional correlation analysis. Whole-brain analysis revealed altered metabolic connectivity in PD, with local decreases in frontolateral cortex and cerebellum and increases in the basal ganglia. Widespread long-distance decreases were present within the frontolateral cortex as opposed to connectivity increases in posterior cortical regions, all suggestive of a global-scale connectivity reconfiguration. The pathology-based analyses revealed significant connectivity impairment in the nigrostriatal dopaminergic pathway and in the regions early affected by α -synuclein pathology. Notably, significant connectivity changes were present in several resting state networks especially in frontal regions. These findings expand previous imaging evidence of altered connectivity in cognitively stable PD patients by showing pathology-based connectivity changes and disease-specific metabolic architecture reconfiguration at multiple scale levels, from the earliest PD phases. These alterations go well beyond the known striato-cortical connectivity derangement supporting *in vivo* an extended neural vulnerability in the PD synucleinopathy.

Parkinson's disease (PD) is a neurodegenerative disease predominantly characterized by abnormal intracellular accumulations of insoluble α -synuclein into fibrils¹. It has been postulated that the synaptic dysfunction caused by the small aggregates of α -synuclein is the initial event leading to neurodegeneration in PD and in other synucleinopathies². Since physiological α -synuclein plays a key role in the regulation of the dopaminergic normal synaptic function, dopaminergic neurons are particularly vulnerable to α -synuclein pathology². Synaptic dysfunction might impair both neurotransmitter release and regulation of synaptic plasticity mechanisms, also producing widespread effects on functional connectivity among distant brain regions which may result in neural networks alterations³. All above evidence suggests that PD can be regarded as a "network-opathy"⁴, and that adopting a network perspective is essential to understand its pathophysiology⁵. During the last years, an increasing number of neuroimaging studies reported networks alterations in the PD brain. The most consistently reported connectivity change is the alteration of the striato-cortical loop, both in the form of microstructural damage, as shown by diffusion tensor imaging, or as functional connectivity changes by resting state fMRI (rs-fMRI) (see refs 5 and 6). Connectivity changes between striatal and cortical regions have been associated with resting tremor⁷, freezing of gait⁸ and overall motor symptoms severity, as measured by UPDRS-III score⁹, thus suggesting that impairment of the cortico-striatal loops is a key phenomenon for the occurrence of motor symptoms in PD⁶. A limited amount of rs-fMRI studies assessed connectivity in non-motor resting state networks, reporting reduced connectivity in (i) default mode network

¹Vita-Salute San Raffaele University, Via Olgettina, 58, 20132, Milan, Italy. ²Division of Neuroscience, San Raffaele Scientific Institute, Via Olgettina, 58, 20132, Milan, Italy. ³Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, piazzale Spedali Civili, 25123, Brescia, Italy. ⁴Parkinson's disease Rehabilitation Centre, FERB ONLUS S. Isidoro Hospital, Trescore, Balneario, Italy. ⁵Nuclear Medicine Unit, Azienda Ospedaliera "Spedali Civili", Spedali Civili Hospital, 25123, Brescia, Italy. ⁶Nuclear Medicine Unit, San Raffaele Hospital, Via Olgettina, 60, 20132, Milan, Italy. Correspondence and requests for materials should be addressed to D.P. (email: perani.daniela@hsr.it)

(DMN), correlating with working memory and visuo-spatial scores¹⁰, (ii) attentional network, also associated with presence of visual hallucinations¹¹ and (iii) fronto-parietal network, correlating with executive performances¹². Altogether, these studies show that several changes in connectivity underlie the symptomatic aspects of PD⁵, and that the dopaminergic degeneration inducing loss of striato-cortical functional connectivity is only part of a larger picture⁹. Notably, as recently suggested, not the dopaminergic cell death, but the abnormal accumulation of α -synuclein could be the initial event leading to neurodegeneration in PD and in other synucleinopathies². α -synuclein aggregation affects key synaptic proteins, impairing neuronal function and axonal transport^{1,2}. These effects on both neurotransmitter release and regulation of synaptic mechanisms can affect activity-dependent signalling and gene expression³ leading to synaptic disconnection and network disintegration^{3,5}.

A unique tool to capture *in vivo* the pathological events that contribute to synaptic dysfunction is [18F]fluorodeoxyglucose with positron emission tomography ([18F]FDG-PET). [18F]FDG-PET is considered as an effective measure of energy consumption in neurons (specifically in synapses)¹³, and its signal has also been associated with synaptic density and function¹⁴, altered intracellular signalling cascades, impaired neurotransmitter release, spreading of proteinopathies, and long distance disconnection (see ref. 15). Crucially, brain energy consumption as measured by [18F]FDG-PET reflects neuronal communication signalling¹⁶, and it is thus strictly interrelated with functional connectivity^{17,18}. Thus, a metabolic network perspective might allow for important insights into local neural vulnerabilities, long-range disconnection, and the effects of neuropathology. In the last years, several approaches have been developed in order to assess metabolic connectivity in the human brain^{19,20}. Based on the assumption that regions whose metabolism is correlated are functionally interconnected²¹, seed-based voxel wise analysis²⁰ and Sparse Inverse Covariance Estimation (SICE) method¹⁹ represent suitable approaches to measure functional interconnections between brain regions. These methods provide results comparable to those derived by rs-fMRI images analyses²², allowing also the application of graph-theoretical analysis to [18F]FDG-PET data¹⁹. SICE method is particularly suitable for the assessment of [18F]FDG-PET brain metabolic connectivity providing reliable estimation even with relatively small sample sizes. This is extremely useful for [18F]FDG-PET connectivity studies in which a single mean image is obtained for each subject and the sample size corresponds to the number of subjects and not to the length of the time series, as in rs-fMRI studies¹⁹.

The SICE method has been previously applied to [18F]FDG-PET data in neurodegenerative diseases for connectome assessment^{19,23,24}. Notably, in our previous work²⁴, we provided a metabolic connectome assessment for dementia with Lewy bodies (DLB), a neurological condition belonging to the α -synuclein spectrum, as PD. To the extent that metabolic connectivity captures the underlying synaptic dysfunction and pathology, the assessment of metabolic connectivity in diseases belonging to same neuropathological spectrum might reveal similar patterns of neural vulnerability. Since connectivity could be a marker of the clinical phenotype²⁵, disease-specific patterns of connectivity changes need to be explored. Metabolic connectivity signatures indeed, might provide a pathology-based and clinically-related endophenotype, allowing a better understanding of differences and consistencies in diseases sharing the same underlying pathology but presenting with different clinical phenotypes.

With the aim to further explore brain metabolic connectivity in the synucleinopathies spectrum, we applied both seed-based and SICE approaches for metabolic connectivity estimation at multiple scale levels in a cohort of PD cognitive stable patients. We considered (i) local and long-distance connectivity in the whole brain, (ii) the dorsal and ventral dopaminergic pathways²⁶, (iii) the spreading of α -synuclein pathology, according to Braak's stages²⁷. In addition, we assessed the possible dysfunctional changes in the high-order resting state networks, namely the attentional, anterior and posterior DMN, executive and motor networks in the same PD patients.

Results

Whole-brain analysis. *Number of connections.* PD metabolic connectivity matrix showed a whole-brain reconfiguration with a prevalent loss of connectivity in frontal and cerebellar structures (Fig. 1A). Statistical testing of the differences in the number of connections in each submatrix across groups revealed significant *local connectivity decreases* within a number of sub-matrices, namely the frontolateral, orbitofrontal, occipital, thalamic, brainstem and cerebellar submatrices. The connectivity impairment in frontolateral and cerebellar submatrices was the most severe. Significant *local connectivity increases* were found instead in the frontal medial, parietal, temporal and basal ganglia submatrices (Fig. 1B).

As for the long-distance connectivity changes, a pattern of widespread long-distance disconnections was found involving the submatrices whose metabolic connectivity was locally decreased as well, namely the frontolateral cortex and, to a lesser extent, the orbitofrontal, brainstem and cerebellar submatrix. Selective decreases in connectivity were found for the basal ganglia submatrix, with the frontolateral, motor, somatosensory, insular and brainstem submatrices. The connectivity between the motor and somatosensory submatrices was decreased as well (see Fig. 1B). All reported differences were statistically significant ($p < 0.001$).

Hubs. According to graph-theory, we identified 16 hubs for the HC group and 11 for the PD group, with the anatomical localizations of the hubs differing between groups. In particular, 13 hub regions were lost in PD compared to HC. Lost hubs were part of frontal regions (i.e. inferior frontal gyrus pars opercularis bilaterally and left pars triangularis), the anterior cingulate cortex, the left precentral gyrus, the right angular gyrus, the left insula, the striatum (i.e. left putamen and left ventral striatum) and cerebellum (Fig. 1C).

Dopamine pathway analysis. A significant loss of connectivity in the *dorsal dopamine pathway* was present in PD vs. HC ($T = -29.578$, $p < 0.001$). The connections from bilateral putamen, precentral and postcentral gyri, dorsolateral prefrontal cortex, and the right supplementary motor area and superior medial frontal gyrus




Figure 1. Whole-brain analysis. (A) Figure shows the whole-brain connectivity matrices of PD and HC (first column), with the red-yellow colour gradient representing the strength of the correlation between two nodes. The second column shows PD and HC connectomes projected on a 3D brain template. A global connectivity reconfiguration is present, with frontal and cerebellar regions being the most affected in PD patients. Node degree, i.e. the number of connections for each region, is represented by the size of each dot. Connection strength is represented by the colour and thickness of each line connecting two nodes. (B) The T-score matrix shows differences in the number of connections within and between each sub-matrix in PD versus HC. Abbreviations: F: Frontal. (C) Figure shows lost hub regions, i.e. nodes that assume the role of hubs in HC but not in PD. Hub identification was based on participation coefficient. Hubs are represented on a 3D brain template using BrainNet toolbox.

were affected. The *mesolimbic pathway* was instead globally spared, with no difference in the comparison to HC in the total number of metabolic connections ($T = -1.529$, $p > 0.05$) (Fig. 2).

All reported differences were statistically significant ($p < 0.001$).

α -synuclein pathology spreading analysis. We found decreased metabolic connectivity between regions early affected by α -synuclein pathology, namely the lower brainstem, pons and midbrain (Fig. 3). Lower brainstem, pons and midbrain also underwent significant metabolic disconnections with the regions later affected by α -synuclein pathology (i.e. belonging to stages 5 and 6). Among regions later affected by pathology, only stage 5 showed significant *local* connectivity derangement ($t = -18.415$, $p < 0.001$), particularly affecting the orbitofrontal cortex. Orbitofrontal cortex also suffered *long-distance* disconnections with the frontolateral cortex, a region belonging to the Braak's stage 6. *Local* connectivity was not affected in Braak's stage 4 nor 6 ($t = 0.199$, $p > 0.05$; $t = -0.776$, $p > 0.05$).

Resting-state networks analysis. Resting-state networks obtained from the seed-based inter-correlation analysis are shown in Fig. 4. Alterations in the metabolic connectivity maps were present in all the analysed resting-state networks. As for the *attentional network*, a disconnection of the dorsolateral prefrontal cortex from the seed (i.e. the inferior parietal lobule) was observed. Regarding the *posterior DMN*, the anterior regions (i.e. ventromedial, orbital and dorsolateral frontal cortex) were completely disconnected from the seed (i.e. posterior cingulate cortex). The *anterior DMN* showed also loss of connectivity between the seed (i.e. anterior cingulate/ventromedial frontal cortex) and the posterior regions of the network. The *motor network* showed reduced connectivity within the cortical regions (i.e. premotor cortex, superior medial frontal gyrus, dorsolateral prefrontal cortex) and a total disconnection with the subcortical regions (i.e. putamen bilaterally) and from the seed. The *executive network* was affected to a lesser extent, with a loss of connectivity in orbitofrontal, lateral inferior parietal and cingulate regions.

Discussion

Previous studies investigating metabolic connectivity in PD mainly focused on the identification of specific patterns of metabolic covariance and their association to motor and cognitive symptoms, using principal component analysis^{28–30}. Our study applied for the first time an alternative approach, namely SICE in combination with seed-based inter-correlation analysis for a multiscale assessment of metabolic connectivity in PD, by exploiting the unique sensitivity of [18F]FDG-PET in capturing the pathological events affecting brain functionality. Metabolic connectivity, as revealed by [18F]FDG-PET, should reflect in particular the neuropathological events




Figure 2. Dopaminergic networks analysis. Figure shows the cortical and subcortical projections of the main dopaminergic pathways (left panel). The dorsal dopamine pathway is affected in PD, showing loss of connectivity and reconfiguration. The mesolimbic pathway is spared, with the overall number of connections in the pathway being preserved. Node degree, i.e. the number of connections for each region, is represented by the size of each dot. Connection strength is represented by the colour and thickness of each line connecting two nodes. Abbreviations: SFG: Superior Frontal Gyrus; MFG: Middle Frontal Gyrus; IFG = Inferior Frontal Gyrus. Box plots (right panel) show the total number of connections in each dopaminergic pathway, for PD and HC. Difference is significant for the dorsal dopamine pathway ($p < 0.001$).

A-synuclein spreading




Figure 3. α -synuclein spreading analysis. Figure shows the progression of α -synuclein pathology according to Braak's staging model (left panel). Metabolic connectivity alterations first appear in the lower brainstem, pons and midbrain (Braak's stages 1, 2, 3) and furthermore spread to the orbitofrontal regions (stage 5). Connectivity between orbitofrontal (stage 5) and frontolateral cortex (stage 6) was also partly affected (right panel). The ROIs were defined according to AAL atlas (see text for details). α -synuclein-spreading connectivity results projected on a 3D brain template for PD and HC groups (right panel). Node degree, i.e. the number of connections for each region, is represented by the size of each dot. Connection strength is represented by the colour and thickness of each line connecting two nodes.

affecting synaptic functions in PD, such as neurodegenerative processes related to aggregation of α -synuclein at the presynapsis², which interferes with synaptophysin³¹ and synapsin-III³² proteins functioning, and neurotransmitters alterations³³.

We assessed whole-brain metabolic connectivity without *a priori* constraints, in order to explore possible local and long-distance disconnections and adaptive compensatory changes in the brain organization. We showed that




Figure 4. Resting-state networks analysis. Figure shows resting-state networks topography in PD (blue overlaid to the anatomical template) and HC (red overlaid to the anatomical template) for (A) anterior and posterior default mode network; (B) attentional, (C) executive networks, (D) motor network. A connectivity derangement is present in all the resting-state systems, particularly in the frontal components of each network. Resting-state networks were obtained using seed-based intercorrelation analysis. Clusters with a minimum spatial extent of 50 voxels are shown, with a voxel-wise significant threshold of $p < 0.01$ FDR-corrected.

early PD is associated with a whole-brain architecture reorganization, with connectivity changes largely affecting frontolateral cortex and cerebellum, both locally and at long-distance.

We also assessed pathology-driven alterations in metabolic connectivity by specifically targeting the metabolic architecture of the dopaminergic pathways and the regions involved in α -synuclein pathology spreading. The connectivity within the dorsal dopamine pathway was selectively affected, with concomitant sparing of the mesolimbic pathway. As for the α -synuclein spreading, metabolic connectivity was more impaired in the regions early affected by α -synuclein pathology (Braak's stages 1–3)²⁷.

Finally, we evaluated the degree to which high-order resting state networks are affected in PD, revealing a common pattern of connectivity impairment, with a major disconnection to and within the frontal regions across all resting state networks.

Altogether, these results show that alterations in PD metabolic connectome are strongly consistent with those found in other synucleinopathies such as DLB (cfr. ref. 24), thus supporting a backbone of shared neuronal vulnerabilities consistent with the common underlying pathology.

Connectivity changes at each scale level are discussed in detail as follows.

The **whole brain analysis** revealed *long-distance connectivity decreases* whose most prominent feature was the widespread disconnections affecting the frontolateral submatrix (see Fig. 1). Previous studies in PD have almost exclusively focused on the fronto-striatal circuit^{34,35}, reporting functional disconnections between wide portions of the frontolateral cortex and striatum³⁴, with metabolic changes in the dorsolateral and anterior prefrontal regions coupled to caudate dopamine depletion³⁵. Cortico-cortical connectivity alterations involving the frontolateral cortex were previously reported in PD, although limited to the connections between frontolateral cortex and premotor/supplementary motor areas³⁶. Our results add further evidence for more widespread frontal connectivity changes, showing altered connections with parietal, occipital and temporal cortices, as well as with the basal ganglia, brainstem and cerebellum. The significance of frontal disconnections for specific PD symptoms remains hitherto to be explored. Fronto-striatal system abnormalities, however, are known to be at the basis of PD executive dysfunction, such as planning, spatial working memory and attentional set-shifting³⁷. This extensive pattern of connectivity derangement supports the major frontal pathophysiology in early PD³⁸.

Cerebellum submatrix showed also widespread long-distance disconnections, particularly with frontolateral and premotor areas. This evidence indicates that also specific cerebellar-cortical networks are involved in PD, together with an abnormal cerebello-thalamic connectivity, which we also found altered³⁹.

The basal ganglia submatrix revealed selective connectivity decreases with the frontolateral, premotor, somatosensory, insular and brainstem submatrices, consistent with previous studies using fMRI, that showed a reduced functional connectivity among striatum and dorsolateral prefrontal cortex⁴⁰, sensorimotor cortex⁴¹ and

brainstem⁹. The disconnection between basal ganglia and brainstem is particularly relevant, since it is the very early locus of PD neuropathology²⁷.

As for the *long-distance connectivity increases*, these were observed in posterior brain regions, namely between the parietal, temporal and occipital cortices. Parietal, occipital and temporal cortices were also the core of a widespread number of connectivity increases involving other cortical and subcortical regions (see Fig. 1). The cerebellum showed also selective connectivity increases, that were previously reported using rs-fMRI and ascribed to a compensatory role of cerebellum during the early PD stages⁴². However, the interpretation of connectivity increases as due to compensatory mechanisms needs a note of caution, since evidence suggesting maladaptive mechanisms also exists (cf. ref. 25). This change in connectivity may indeed reflect ineffective “compensatory” mechanism present in the early PD phase. As all PD patients included in the study were cognitively stable, we might also argue that the presence of compensatory mechanisms acting particularly in the posterior brain regions might contribute to the preservation of cognitive functioning in early PD. A progressive posterior cortical impairment is thought to be related to cognitive decline and development of dementia in PD⁴³.

As for *local connectivity decreases*, frontolateral, orbitofrontal and cerebellar submatrices suffered the major loss of local connectivity (see Fig. 1). The frontal lobe dysfunction is an established feature of PD³⁸, and considered a major consequence of the striatal dopaminergic deficits, running through the strong interconnections between frontal cortex and striatal regions³⁸. Consistently, reductions in glucose metabolism in both prefrontal and orbitofrontal regions have been reported in PD and associated with dopaminergic striatal depletion^{35, 44}. Intra-cortical dopamine deficits have been suggested to play a role in the regulation of prefrontal activity in PD, with dopamine depletion leading to defective activation of the dorsolateral prefrontal cortex during motor tasks⁴⁵.

As for the cerebellum local loss of connectivity, we might argue that a crucial role might be played by pathological changes such as α -synuclein pathology⁴⁶, dopaminergic degeneration⁴², loss of dopaminergic D₁-D₃ receptors⁴⁷, atrophy⁴⁸, and white matter damage⁴⁹. Cerebellum is involved in the planning and execution of motor movements, postural control and tremor as well as in a wide range of cognitive functions³⁹ and its derangement, as clearly shown in the present paper, crucially highlights its role in PD.

We found *local connectivity increases* in cortical temporal, parietal and occipital regions that were previously interpreted as compensatory mechanisms, occurring in the extra-striatal regions^{50, 51} (see Fig. 1). In addition, we found local striatal connectivity increases, as also previously reported^{40, 41}. Compensatory mechanisms within the striatum have been suggested to play a role in particular during the very early disease phases, with extra-striatal compensatory mechanisms acquiring importance with disease progression⁵⁰. A recent study has shown that striatal compensatory mechanisms are pivotal to compensate for striatal dopaminergic depletion and maintaining a normal cognitive functioning⁵².

As for the **dopaminergic systems analysis**, the results notably showed a different vulnerability of the two dopaminergic systems, with a significant loss of connectivity in the dorsal dopamine pathway, and a preserved connectivity in the mesolimbic pathway (see Fig. 2). Dopamine depletion impairs the frontostriatal functional connectivity contributing to the pattern of altered metabolic connectivity here observed⁵³. In addition, α -synuclein plays a key role in both dopaminergic neurotransmission pathways, i.e. regulating the filling and fusion of vesicles via vesicular monoamine transporter 2 and the dopamine reuptake via dopamine transporter². It has been shown that substantia nigra neurons are more vulnerable to α -synuclein pathology than ventral tegmental area neurons, possibly due to the higher energy demand of the former⁵⁴. The present findings confirm for the first time at the “metabolic level” the specific dorsal dopamine pathway involvement in early PD patients. Comparable findings were also reported in our previous work on metabolic connectivity in DLB, thus showing that a major vulnerability of the dorsal dopamine pathway is not a disease-specific feature of PD, but extends to other diseases in the synucleinopathies spectrum²⁴.

The pattern analysis of **α -synuclein pathology spreading** revealed altered metabolic connectivity in the regions early affected by α -synuclein pathology (see Fig. 3). The specific connectivity impairment involving the regions of interest (ROIs) part of the first three Braak’s stages (i.e. midbrain, pons and lower brainstem) is consistent with the pathology model postulating that the clinical signs of parkinsonism appear when α -synuclein pathology reaches the third stage, and degeneration of substantia nigra occurs²⁷. Notably, these regions were also disconnected at long-distance from regions later affected by α -synuclein pathology, i.e. the regions belonging to stage 5 and 6.

We also found a partial local connectivity impairment in stage 5 (i.e. the orbitofrontal cortex) and in stage 6 (i.e. the frontolateral cortex). The orbitofrontal and frontal lateral cortex have consistently been reported as loci of damage in PD^{49, 55}, due to the dopamine-mediated striato-frontal disconnection^{35, 38, 44}. Stage 4 did not show significant local connectivity changes. From the methodological standpoint, it must be acknowledged that the anatomically-restricted analyses for the α -synuclein spreading were performed using the automated anatomical labelling atlas (AAL) functional-anatomical regions, not specifically constructed for pathology-driven analysis. Stage 4, that includes temporal mesocortex and allocortex, might have suffered for the ROIs subdivision derived from the AAL. In the future, atlases based on histopathology may become available, allowing this limitation to be overcome. Alternatively, it is possible that the “hippocampus, parahippocampus and amygdala” ROIs we chose for Stage 4, could be less affected by α -synucleopathy in PD, given the complete absence of memory related deficits in our series. Taken together, these results support the link between α -synuclein accumulation and synaptic dysfunction as measured by [18F]FDG-PET and notably give an *in vivo* support to Braak’s staging model²⁷. Also, this result is consistent with our previous α -synuclein-spreading-based connectomics analysis in DLB²⁴, thus *in vivo* supporting a common pattern of α -synuclein-spreading across the two diseases belonging to the same pathology spectrum.

As for **resting-state networks analysis**, we found a loss of connectivity in the dorsolateral prefrontal cortex and the parietal regions, affecting the attentional network (see Fig. 4B), consistently with a previous rs-fMRI study in PD¹¹, which reported also an association between the impairment of attention network hubs and poor performance in perceptual tasks.

As for *DMN*, there was a loss of connectivity in both the anterior and posterior components (see Fig. 4A). This pattern of disconnection has been previously described in normal aging and, at an accelerated rate, in Alzheimer's disease⁵⁶. The author speculated that this pattern of disconnections could be due to age-related increasing synaptic inefficiency, to which subject vulnerable to develop Alzheimer's disease would be more susceptible⁵⁶. Our results suggest that not only Alzheimer's disease but also PD would produce a similar pattern of connectivity impairment in the DMNs that might be prodromal to further development of cognitive symptoms. Notably, recent studies have shown that DMN is disrupted even in cognitively unimpaired PD patients^{10, 57}. It has been suggested that DMN disruption mainly arises as a direct consequence of PD pathology⁵⁷ and maximally as the result of PD dopaminergic impairment⁵⁸. Consistently, it was shown that administration of drugs enhancing dopaminergic activity is able to restore normal DMN functioning in PD⁵⁸.

As for the *executive network*, our results strengthen the link between the dysfunction of the executive network and the alteration of frontal-striatal connectivity (see Fig. 4C). Previous rs-fMRI studies in PD also reported abnormal connectivity within this network⁵⁹, as well as abnormal interactions between the executive network and DMN⁶⁰. The impairment in prefrontal and orbitofrontal regions, considered to be at the basis of the executive dysfunctions in PD, might follow frontal-striatal dopaminergic imbalance⁶¹. Notwithstanding the role of frontal impairment in the executive dysfunction is well-recognized in PD, it is not clear whether it contributes to cognitive decline and dementia development⁶². An early predictor of dementia in PD is instead the posterior cortical damage⁶². The dual syndrome hypothesis considers the fronto-striatal dysfunction as a characteristic of non-demented PD patients, and the posterior cortical and temporal lobe dysfunction as a signature of rapid cognitive decline⁶³.

This study, together with our previous work in DLB²⁴, allows for a comparative picture of the metabolic connectome in the two most diffuse α -synucleinopathies. Notably, the whole-brain analyses in PD and DLB groups revealed consistencies and substantial differences. As for the differences, PD showed an extensive decrease of connectivity in frontal regions, with compensatory connectivity increases involving occipital and posterior cortical regions, whereas an occipital connectivity impairment was present in DLB, together with frontal compensatory connectivity increases. This opposite pattern of anterior-posterior connectivity changes in early cognitive stable PD and in DLB patients might be of crucial clinical relevance. It is consistent with the prevalent frontal functional changes previously reported in non-demented PD patients, as opposed to the posterior impairment associated with dementia in PD and DLB. The different impairment of anterior-posterior connectivity might reflect the different vulnerability of the cholinergic system in PD and DLB⁶¹, leading to disease-specific patterns of neuronal dysfunction^{43, 64–66}, and metabolic connectivity changes, here reported for the first time.

As for the consistencies, cerebellum, mesencephalic-pontine and striatal regions showed comparable patterns of altered connectivity in both PD and DLB, locally and at long-distance. Pathology-driven analyses provided similar results in the two parkinsonian conditions, with the greatest connectivity impairment in the dorsal dopamine pathway and in the regions early affected by α -synuclein pathology. Further studies within this spectrum, involving populations of PD patients with mild cognitive impairment or dementia, DLB patients at different disease phase and MSA cases, will provide the evidence for common and disease-specific connectivity alterations also linked to the specific clinical phenotypes.

In conclusion, our results show that metabolic connectivity is affected in early PD at multiple scale levels, with (i) a thorough reconfiguration of the global whole-brain architecture, mainly affecting frontal connectivity, (ii) a metabolic connectivity disruption underlying a major impairment in the dorsal dopamine neurotransmission system and in the early spreading of α -synuclein pathology, and (iii) reconfigurations in high-order resting state networks affecting in particular the frontal regions. The reported results point at a disease-specific pattern of frontal disconnection and posterior connectivity compensation, consistent with the “*dual syndrome hypothesis*”⁶³. The present results support the emerging hypothesis that PD is a widespread neurodegenerative disease at multiple scale levels (cfr. ref. 6) and that the era of the axiom “PD equals dopaminergic dysregulation” needs to be rewritten.

Materials and Methods

Subjects. Thirty-four idiopathic PD patients without any cognitive impairment at baseline and stable during 4-years follow-up were retrospectively collected from the clinical and imaging database of the Neurology Unit, Department of Clinical and Experimental Sciences, at the University of Brescia, Brescia, Italy. The clinical diagnosis was made according to the UK Brain Bank Criteria⁶⁷ by movement disorders specialist (A.P. and A.A.), considering full medical history, neurological examination (including UPDRS-III in ON condition) and a standard neuropsychological assessment. All patients included underwent structural imaging (magnetic resonance imaging or computed tomography (CT)) in order to exclude prominent cortical or subcortical infarcts or brain/iron accumulation or atypical parkinsonian disorders. Stringent exclusion criteria were applied: presence of deep brain stimulation, verified genetic mutation known to cause PD, concomitant psychiatric or other neurological disorder, hallucination, psychosis or antipsychotic drug use, history of drug or alcohol abuse, mild cognitive impairment. The study crucially excluded PD patients with a mild cognitive impairment or dementia diagnosis defined according to the level II MDS criteria using the neuropsychological assessment and cut-offs recently published⁶⁸. The PD patients included underwent [18F]FDG-PET scans for research purposes. The group comprised 18 males and 16 females with a mean age of 63.71 ± 11.70 years and mean disease duration of 4.5 ± 2.65 years. No patients included in the study developed dementia at 4-year clinical and neuropsychological follow-up, thus presenting a stable cognitive functioning at least until 8.5 ± 2.65 years of disease duration. All patients were taking antiparkinsonian medications and had a mean Levodopa equivalent daily dose of 422 ± 316 mg. Demographic, clinical and cognitive features in PD and healthy controls (HC) groups are reported in Table 1.

[18F]FDG-PET scans of 34 age-matched cognitively normal HC were included for comparison. The group comprised 17 males and 17 females with a mean age of 65.55 ± 8.85 years. Age and gender did not differ significantly between PD and HC groups (Age: $T = 0.433$, $p = 0.667$; Gender: $X^2 = 0.059$, $p = 0.808$).

	PD	HC	<i>p</i>
N	34	34	—
Gender (M/F)	18/16	17/17	0.808
Age (years \pm sd)	63.71 \pm 11.70	65.55 \pm 8.85	0.667
Disease Duration (years \pm sd)	4.5 \pm 2.65	—	—
UPDRS-III (ON)	14.7 \pm 1.2	—	—
Hoehn & Yahr staging, N (%)			
1	9 (26%)	—	—
2	15 (44%)	—	—
3	10 (30%)	—	—
4	—	—	—
MMSE	28.61 \pm 0.28	—	—
Total LEDD (mg/die \pm sd)	422 \pm 316	—	—

Table 1. Demographic, clinical and cognitive features of the study groups. **Abbreviations:** HC, healthy controls; LEDD, Levodopa equivalent daily dose; MMSE, Mini-Mental State Examination; PD, Parkinson's disease patients; UPDRS-III, Unified Parkinson's Disease Rating Scale- motor score.

All subjects or their informants/caregivers gave their written informed consent to the experimental procedure, as approved by the Ethical Committees of Spedali Civili di Brescia and of San Raffaele Hospital. The protocol conformed to the ethical standards of the Declaration of Helsinki for protection of human subjects.

[18F]FDG-PET image acquisition and pre-processing. The [18F]FDG-PET scans were acquired using a Discovery STE PET scanner (3.27 mm thickness; 5.55 mm in-plane full width at half maximum (FWHM)), manufactured by GE Healthcare. The [18F]FDG-PET acquisition procedures conformed to the European Association of Nuclear Medicine guidelines⁶⁹. Static emission images were acquired 45 min after injecting 185–250 MBq of [18F]FDG via a venous cannula, with scan duration of 15 min.

Uniform reconstruction protocols were applied in order to factor out possible sources of variability. All images were reconstructed using an ordered subset-expectation maximization algorithm (OSEM). Attenuation correction was based on CT scans. Each reconstructed image was visually inspected in order to check for major artefacts, i.e. defective image uniformity/orientation or attenuation correction due to mismatch between CT and PET images.

Images underwent general pre-processing procedures, using the MATLAB (Mathworks Inc., Sherborn, Mass., USA) based software SPM5 (<http://www.fil.ion.ucl.ac.uk/spm/software/SPM5/>). Each image was first normalized to a [18F]FDG-PET specific template registered to the MNI standard space⁷⁰ and spatially smoothed with an 8 mm isotropic 3D Gaussian FWHM kernel. Images were then proportionally scaled to the global mean.

Whole-brain and pathology-driven metabolic connectivity analyses. We used **SICE**, a method previously validated by Huang *et al.*¹⁹. SICE-based analyses involve the definition of the basic units of each network, i.e. the ROIs/nodes. The [18F]FDG-PET signal is extracted from each ROI and from each subject, thus obtaining Subjects \times ROIs matrices. SICE algorithm is then applied on the Subjects \times ROIs matrices in order to estimate the metabolic connectivity matrices. Graph theory measures are computed from the metabolic connectivity matrices and a bootstrapping procedure is performed in order to test differences between HC and PD groups.

Node selection and ROIs definition. For the *whole-brain*, we created the whole-brain metabolic connectivity matrix (i.e. the full-matrix), considering cortical, subcortical, cerebellar, and brainstem regions (121 \times 121 ROIs). Following Huang and colleagues (2010), the full-matrix was subdivided into 13 sub-matrices, representative of larger brain regions¹⁹. We considered frontolateral, fronto-orbital, frontal medial, motor, somatosensory, parietal, occipital, temporal, insula, thalamus, basal ganglia, brainstem and cerebellar submatrices for statistical testing (see Fig. 3B).

In the pathology-driven connectivity analyses, we focused on the neural networks related to PD pathology, namely the dopaminergic neurotransmission pathways²⁶ and the brain regions affected by the spreading of α -synuclein according to Braak's staging²⁷.

For the *dopaminergic system analysis*, we considered ROIs pertaining to the dorsal and the mesolimbic dopamine pathways, as detailed elsewhere²⁴. The small dopaminergic nuclei, i.e. substantia nigra and ventrotectal area, were not included in the analysis, due to the limited spatial resolution of PET method and the lack of reference atlases for these regions.

As for the *α -synuclein spreading analysis*, we considered the staging system proposed by Braak and colleagues (2003)²⁷. Within the α -synuclein network, we considered the lower brainstem and pons for stages 1 and 2 respectively, since these regions contain the grey matter nuclei early affected by α -synuclein pathology in PD, i.e. the dorsal IX-X motor nuclei, intermediate reticular zone, caudal raphe nuclei, gigantocellular reticular nucleus and coeruleus/subcoeruleus complex; the midbrain, which includes the pathological hallmark of the disease, namely the substantia nigra *pars compacta* for stage 3; hippocampus, parahippocampal gyrus, and amygdala for stage 4; the temporal lobe, anterior cingulate, insular and orbitofrontal cortices for stage 5; the remaining neocortical areas, with the exception of the primary sensory areas and the primary motor fields, for stage 6²⁷ (Fig. 3).

All the above mentioned ROIs were derived from the same atlas, i.e. AAL⁷¹, with the exception of ROIs not included in the AAL, namely (i) the brainstem ROIs, (midbrain, pons, lower brainstem) derived from the

WFUPickAtlas Talairach Daemon Lobar Atlas⁷²; (ii) the dorsal and ventral striatum ROIs defined considering the basal ganglia boundaries as provided by the AAL and the subdivision provided by the Tziortzi and colleagues (2011) guidelines⁷³.

Construction of Brain Connectivity Matrices. Estimation of Brain Connectivity Matrices was based on SICE, a method suitable for metabolic connectivity studies, where the traditional maximum likelihood estimation method cannot be reliably applied¹⁹. Construction of Brain Connectivity Matrices was performed using GraphVar toolbox⁷⁴. SICE allows to estimate the structure of the metabolic connectivity matrix by imposing a sparsity constraint on the maximum likelihood estimate of the inverse covariance matrix¹⁹. SICE provides a robust estimation of the binary structure of the inverse covariance matrix, but it does not allow to estimate the strength of non-zero entries due to shrinkage²³. As a consequence, only information on the presence or absence of metabolic connections can be used to build the brain connectivity model¹⁹. Though information on the strength of the metabolic connections are not provided by SICE, a quasi-measure of strength can be obtained by summing up unweighted binary matrices estimated at different density levels¹⁹. Only for visualization purposes, we used Stability Approach to Regularization Selection (StARS) (see below) applied to matrices at a predefined range of densities (i.e. 3–18% with an incremental interval of 3%), in order to obtain unweighted binary matrices at different densities. By summing up the six unweighted binary matrices for each group and analysis, summary quasi-weighted matrices were obtained and represented in a 3D brain template using BrainNet toolbox⁷⁵.

Given that robustness of the sparse estimation depends on matrix density⁷⁶, density level must be carefully chosen to ensure that the covariance matrix is sparse¹⁹. In SICE, density level is controlled for by a regularization parameter λ ¹⁹. Different strategies have been proposed for density selection⁷⁷ but no gold standard was established for selection of λ using SICE. A new criterion for λ selection, called StARS, has been recently proposed⁷⁸. StARS allows to select the minimum value of λ necessary to ensure matrix sparsity and replicability under random sampling, avoiding the risk of massive false positives without failing to capture the true structure of the connectivity matrix⁷⁸. In order to select the optimal sparsity level for each group, StARS⁷⁸ was applied to both PD and HC matrices. The resulting matrices were used for statistical testing.

Graph theory and statistical analyses. For the whole-brain analysis, we computed the degree and the participation coefficient of each node using Brain Connectivity Toolbox⁷⁶. Participation coefficient (Pi) was defined as:

$$P_i = 1 - \sum_{m=1}^{N_m} \left(\frac{k_i(m)}{k_i} \right)^2$$

where N_m is the number of modules, $k_i(m)$ is the number of links of node i to nodes in module m , and k_i is the total degree of node i ⁷⁹. Participation coefficient was adopted in order to identify the most important regions/nodes of the network, i.e. the hubs⁸⁰ by setting a threshold at 1.25 standard deviation over the average participation coefficient.

Considering the whole-brain sub-matrix-based analysis, we calculated the total number of within or local connections (i.e. connections linking two nodes in the same sub-matrix) and the total number of between or long-distance connections (i.e. connections linking two nodes belonging to different sub-matrices). For the pathology-driven networks, we computed the total number of connections and nodal degree within each network.

A bootstrapping procedure was adopted in order to rigorously test differences between groups¹⁹. For each connectivity matrix, we extracted 1000 bootstrap samples of 34 subjects, with replacement, for both PD and HC groups. Based on PD and HC respective bootstrap samples, we performed hypothesis testing for each SICE analysis. For the whole-brain analysis, we tested significant differences between PD and HC groups in the total number of connections within each submatrix and between each pair of submatrices. For the pathology-driven analysis, we tested the null hypothesis that the total number of connections in each dopaminergic pathway and in each Braak's stage was equal across groups. Multiple independent t-tests with Bonferroni correction were performed for each analysis. For a thorough explanation of the statistical testing procedure see ref. 19.

Resting-state networks metabolic connectivity. We used **seed-based inter-correlation analysis**, a method previously validate by Lee and colleagues (2008) for [18F]FDG-PET data²⁰. We focused our analyses on the attentional, DMN (anterior and posterior), executive and motor networks. For each network, a seed region was selected on the basis of previous literature, namely the inferior parietal lobule for the *attentional network*⁸¹, the anterior cingulate cortex/ventromedial prefrontal cortex for the *anterior DMN*⁵⁶, the posterior cingulate cortex for the *posterior DMN*⁸², the dorsolateral prefrontal cortex for the *executive network*⁸³, and the precentral gyrus for the *motor network*⁸⁴. For each group and network, [18F]FDG-PET signal extracted from the designated seed was entered as covariate in a Multiple Regression Model in SPM5 and used to predict [18F]FDG-PET signal elsewhere in the brain, thus allowing the estimation of the corresponding resting state network. Voxel-wise False Discovery Rate (FDR)-corrected $p < 0.01$ was considered statistically significant.

Data Availability. All relevant data are included in this published article.

References

- Spillantini, M. G. & Goedert, M. Synucleinopathies: Past, Present and Future. *Neuropathol. Appl. Neurobiol.* **42**, 3–5 (2016).
- Calo, L., Wegrzynowicz, M., Santivañez-Perez, J. & Grazia Spillantini, M. Synaptic failure and α -synuclein. *Mov. Disord.* **31**, 169–177 (2016).
- Palop, J. J., Chin, J. & Mucke, L. A network dysfunction perspective on neurodegenerative diseases. *Nature* **443**, 768–773 (2006).
- Warren, J. D., Rohrer, J. D. & Hardy, J. Disintegrating brain networks: from syndromes to molecular nexopathies. *Neuron* **73**, 1060–12 (2012).

5. Bellucci, A. *et al.* Parkinson's disease: from synaptic loss to connectome dysfunction. *Neuropathol. Appl. Neurobiol.* **42**, 77–94 (2015).
6. Cerasa, A., Novellino, F. & Quattrone, A. Connectivity Changes in Parkinson's Disease. *Curr. Neurol. Neurosci. Rep.* **16**, 91 (2016).
7. Helmich, R. C., Janssen, M. J. R., Oyen, W. J. G., Bloem, B. R. & Toni, I. Pallidal dysfunction drives a cerebellothalamic circuit into Parkinson tremor. *Ann. Neurol.* **69**, 269–281 (2011).
8. Shine, J. M. *et al.* Freezing of gait in Parkinson's disease is associated with functional decoupling between the cognitive control network and the basal ganglia. *Brain* **136**, 3671–3681 (2013).
9. Hacker, C. D., Perlmutter, J. S., Criswell, S. R., Ances, B. M. & Snyder, A. Z. Resting state functional connectivity of the striatum in Parkinson's disease. *Brain* **135**, 3699–3711 (2012).
10. Tessitore, A. *et al.* Default-mode network connectivity in cognitively unimpaired patients with Parkinson disease. *Neurology* **79**, 2226–2232 (2012).
11. Shine, J. M. *et al.* The role of dysfunctional attentional control networks in visual misperceptions in Parkinson's disease. *Hum. Brain Mapp.* **35**, 2206–2219 (2014).
12. Lebedev, A. V. *et al.* Large-scale resting state network correlates of cognitive impairment in Parkinson's disease and related dopaminergic deficits. *Front. Syst. Neurosci.* **8**, 45 (2014).
13. Magistretti, P. J., Pellerin, L., Rothman, D. L. & Shulman, R. G. Energy on Demand. *Science (80-)* **283**, 496–497 (1999).
14. Rocher, A. B., Chapon, F., Blaizot, X., Baron, J. C. & Chavoix, C. Resting-state brain glucose utilization as measured by PET is directly related to regional synaptophysin levels: A study in baboons. *Neuroimage* **20**, 1894–1898 (2003).
15. Perani, D. FDG-PET and amyloid-PET imaging: the diverging paths. *Curr. Opin. Neurol.* **27**, 405–13 (2014).
16. Attwell, D. & Laughlin, S. B. An energy budget for signaling in the grey matter of the brain. *J. Cereb. Blood Flow Metab.* **21**, 1133–1145 (2001).
17. Passow, S. *et al.* Default-mode network functional connectivity is closely related to metabolic activity. *Hum. Brain Mapp.* **36**, 2027–2038 (2015).
18. Riedel, V. *et al.* Metabolic connectivity mapping reveals effective connectivity in the resting human brain. *Proc Natl Acad Sci USA* **113**, 428–33 (2016).
19. Huang, S. *et al.* Learning brain connectivity of Alzheimer's disease by sparse inverse covariance estimation. *Neuroimage* **50**, 935–49 (2010).
20. Lee, D. S. *et al.* Metabolic connectivity by interregional correlation analysis using statistical parametric mapping (SPM) and FDG brain PET; methodological development and patterns of metabolic connectivity in adults. *Eur. J. Nucl. Med. Mol. Imaging* **35**, 1681–91 (2008).
21. Horwitz, B., Duara, R. & Rapoport, S. I. Intercorrelations of glucose metabolic rates between brain regions: application to healthy males in a state of reduced sensory input. *J. Cereb. Blood Flow Metab.* **4**, 484–99 (1984).
22. Di, X., Biswal, B. B. & and Alzheimer's Disease Neuroimaging Initiative. Metabolic Brain Covariant Networks as Revealed by FDG-PET with Reference to Resting-State fMRI Networks. *Brain Connect.* **2**, 275–283 (2012).
23. Titov, D. *et al.* Metabolic connectivity for differential diagnosis of dementing disorders. *J. Cereb. Blood Flow Metab.* **37**, 252–62 (2017).
24. Caminiti, S. P. *et al.* Metabolic connectomics targeting brain pathology in dementia with Lewy bodies. *J. Cereb. Blood Flow Metab.* doi:10.1177/0271678X16654497 (2016).
25. Pievani, M., Filippini, N., van den Heuvel, M. P., Cappa, S. F. & Frisoni, G. B. Brain connectivity in neurodegenerative diseases—from phenotype to proteinopathy. *Nat. Rev. Neurol.* **10**, 620–633 (2014).
26. Nieuwenhuys, R., Voogd, J. & Van Huijzen, C. *The human central nervous system: a synopsis and atlas.* (Springer Science & Business Media 2007).
27. Braak, H. *et al.* Staging of brain pathology related to sporadic Parkinson's disease. *Neurobiol. Aging* **24**, 197–211 (2003).
28. Eidelberg, D. *et al.* The metabolic topography of parkinsonism. *J. Cereb. blood flow Metab.* **14**, 783–801 (1994).
29. Huang, C. *et al.* Metabolic brain networks associated with cognitive function in Parkinson's disease. *Neuroimage* **34**, 714–723 (2007).
30. Spetsieris, P. G. *et al.* Metabolic resting-state brain networks in health and disease. *Proc. Natl. Acad. Sci. USA* **112**, 2563–8 (2015).
31. Koch, J. C. *et al.* Alpha-Synuclein affects neurite morphology, autophagy, vesicle transport and axonal degeneration in CNS neurons. *Cell Death Dis* **6**, e1811 (2015).
32. Zaltieri, M. *et al.* α -synuclein and synapsin III cooperatively regulate synaptic function in dopamine neurons. *J. Cell Sci.* **128**, 2231–43 (2015).
33. Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K. & Seitelberger, F. 1973. Brain dopamine and the syndromes of Parkinson and Huntington Clinical, morphological and neurochemical correlations. *J. Neurol. Sci.* **20**, 415–455 (1973).
34. Xu, J. *et al.* Abnormal fronto-striatal functional connectivity in Parkinson's disease. *Neurosci. Lett.* **613**, 66–71 (2016).
35. Polito, C. *et al.* Interaction of caudate dopamine depletion and brain metabolic changes with cognitive dysfunction in early Parkinson's disease. *Neurobiol. Aging* **33**, 206.e29–206.e39 (2012).
36. Rowe, J. *et al.* Attention to action in Parkinson's disease: impaired effective connectivity among frontal cortical regions. *Brain* **125**, 276–289 (2002).
37. Kehagia, A. A., Barker, R. A. & Robbins, T. W. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. *Lancet Neurol.* **9**, 1200–1213 (2010).
38. Taylor, A. E., Saint-Cur, J. A. & Lang, A. E. Frontal Lobe Dysfunction in Parkinson's Disease. *Brain* **109**, 845–883 (1986).
39. Balsters, J. H., Laird, A. R., Fox, P. T. & Eickhoff, S. B. Bridging the gap between functional and anatomical features of cortico-cerebellar circuits using meta-analytic connectivity modeling. *Hum. Brain Mapp.* **35**, 3152–3169 (2014).
40. Wu, T. *et al.* Functional connectivity of cortical motor areas in the resting state in Parkinson's disease. *Hum. Brain Mapp.* **32**, 1443–1457 (2011).
41. Sharman, M. *et al.* Parkinson's disease patients show reduced cortical-subcortical sensorimotor connectivity. *Mov. Disord.* **28**, 447–454 (2013).
42. Wu, T. & Hallett, M. The cerebellum in Parkinson's disease. *Brain* **136**, 696–709 (2013).
43. Bohnen, N. I. *et al.* Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study. *J. Nucl. Med.* **52**, 848–55 (2011).
44. Berti, V. *et al.* Brain metabolic correlates of dopaminergic degeneration in de novo idiopathic Parkinson's disease. *Eur. J. Nucl. Med. Mol. Imaging* **37**, 537–544 (2010).
45. Sabatini, U., Boulanouar, K., Fabre, N. & Martin, F. Cortical motor reorganization in akinetic patients with Parkinson's disease A functional MRI study. *Brain* **123**, 394–403 (2000).
46. Seidel, K. *et al.* Involvement of the cerebellum in Parkinson's disease and Dementia with Lewy bodies. *Ann. Neurol.* doi:10.1002/ana.24937 (2017).
47. Hurlley, M. J., Mash, D. C. & Jenner, P. Markers for dopaminergic neurotransmission in the cerebellum in normal individuals and patients with Parkinson's disease examined by RT-PCR. *Eur. J. Neurosci.* **18**, 2668–2672 (2003).
48. Callaghan, C. O. *et al.* Cerebellar atrophy in Parkinson's disease and its implication for network connectivity. *Brain* **139**(Pt.3), 845–55 (2016).
49. Zhang, K. *et al.* Voxel-based analysis of diffusion tensor indices in the brain in patients with Parkinson's disease. *Eur. J. Radiol.* **77**, 269–273 (2011).

50. Bezdard, E., Crossman, A. R., Gross, C. E. & Brotchie, J. M. Structures outside the basal ganglia may compensate for dopamine loss in the presymptomatic stages of Parkinson's disease. *FASEB J* **15**, 1092–4 (2001).
51. Pollok, B. *et al.* Increased SMA – M1 coherence in Parkinson's disease — Pathophysiology or compensation? *Exp. Neurol.* **247**, 178–181 (2013).
52. Poston, K. L. *et al.* Compensatory neural mechanisms in cognitively unimpaired Parkinson disease. *Ann. Neurol.* **79**, 448–463 (2016).
53. Nagano-Saito, A. *et al.* Dopamine Depletion Impairs Frontostriatal Functional Connectivity during a Set-Shifting Task. *J. Neurosci.* **28**, 3697–3706 (2008).
54. Fu, Y. H., Paxinos, G., Watson, C. & Halliday, G. M. The substantia nigra and ventral tegmental dopaminergic neurons from development to degeneration. *J. Chem. Neuroanat.* **76**(Pt B), 98–107 (2015).
55. Ko, J. H. *et al.* Prefrontal dopaminergic receptor abnormalities and executive functions in Parkinson's disease. *Hum. Brain Mapp.* **34**, 1591–1604 (2013).
56. Jones, D. T. *et al.* Age-related changes in the default mode network are more advanced in Alzheimer disease. *Neurology* **77**, 1524–1531 (2011).
57. Yao, N. *et al.* The default mode network is disrupted in parkinson's disease with visual hallucinations. *Hum. Brain Mapp.* **35**, 5658–5666 (2014).
58. Delaveau, P. *et al.* Dopaminergic modulation of the default mode network in Parkinson's disease. *Eur. Neuropsychopharmacol.* **20**, 784–792 (2010).
59. Rosenberg-Katz, K. *et al.* Fall risk is associated with amplified functional connectivity of the central executive network in patients with Parkinson's disease. *J. Neurol.* **262**, 2448–2456 (2015).
60. Putcha, D., Ross, R. S., Cronin-Golomb, A., Janes, A. C. & Stern, C. E. Altered intrinsic functional coupling between core neurocognitive networks in Parkinson's disease. *NeuroImage Clin.* **7**, 449–455 (2015).
61. Pagonabarraga, J. & Kulisevsky, J. Cognitive impairment and dementia in Parkinson's disease. *Neurobiol. Dis.* **46**, 590–596 (2012).
62. Williams-Gray, C. H. *et al.* The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. *Brain* **132**, 2958–2969 (2009).
63. Kehagia, A. A., Barker, R. A. & Robbins, T. W. Cognitive impairment in Parkinson's disease: The dual syndrome hypothesis. *Neurodegener. Dis.* **11**, 79–92 (2012).
64. Hosokai, Y. *et al.* Distinct patterns of regional cerebral glucose metabolism in Parkinson's disease with and without mild cognitive impairment. *Mov. Disord.* **24**, 854–862 (2009).
65. Garcia-Garcia, D. *et al.* Posterior parietooccipital hypometabolism may differentiate mild cognitive impairment from dementia in Parkinson's disease. *Eur. J. Nucl. Med. Mol. Imaging* **39**, 1767–1777 (2012).
66. Vander Borght, T. *et al.* Cerebral metabolic differences in Parkinson's and Alzheimer's diseases matched for dementia severity. *J. Nucl. Med.* **38**, 797–802 (1997).
67. Hughes, A. J., Daniel, S. E., Kilford, L. & Lees, A. J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. *J. Neurol. Neurosurg. Psychiatry* **55**, 181–184 (1992).
68. Pilotto, A. *et al.* Vascular Risk Factors and Cognition in Parkinson's Disease. *J. Alzheimers. Dis.* **51**, 563–570 (2016).
69. Varrone, A. *et al.* EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. *Eur. J. Nucl. Med. Mol. Imaging* **36**, 2103–2110 (2009).
70. Della Rosa, P. A. *et al.* A Standardized [(18)F]-FDG-PET Template for Spatial Normalization in Statistical Parametric Mapping of Dementia. *Neuroinformatics* **12**, 575–93 (2014).
71. Tzourio-Mazoyer, N. *et al.* Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. *Neuroimage* **15**, 273–89 (2002).
72. Lancaster, J., Rainey, L., Summerlin, J. & Freitas, C. Automated labeling of the human brain: a preliminary report on the development and evaluation of a {...}. *Hum. Brain Mapp.* **242**, 238–242 (1997).
73. Tziortzi, A. C. *et al.* Imaging dopamine receptors in humans with [11C]-(-)-PHNO: Dissection of D3 signal and anatomy. *Neuroimage* **54**, 264–277 (2011).
74. Kruschwitz, J. D., List, D., Waller, L., Rubinov, M. & Walter, H. GraphVar: A user-friendly toolbox for comprehensive graph analyses of functional brain connectivity. *J. Neurosci. Methods* **245**, 107–15 (2015).
75. Xia, M., Wang, J. & He, Y. BrainNet Viewer: a network visualization tool for human brain connectomics. *PLoS One* **8**, e68910 (2013).
76. Rubinov, M. & Sporns, O. Complex network measures of brain connectivity: uses and interpretations. *Neuroimage* **52**, 1059–69 (2010).
77. van Wijk, B. C. M., Stam, C. J. & Daffertshofer, A. Comparing brain networks of different size and connectivity density using graph theory. *PLoS One* **5** (2010).
78. Liu, H., Roeder, K. & Wasserman, L. Stability Approach to Regularization Selection (StARS) for High Dimensional Graphical Models. *Adv. Neural Inf. Process. Syst.* **24**, 1432–1440 (2010).
79. Guimerà, R. & Nunes Amaral, L. A. Functional cartography of complex metabolic networks. *Nature* **433**, 895–900 (2005).
80. Power, J. D., Schlaggar, B. L., Lessov-Schlaggar, C. N. & Petersen, S. E. Evidence for Hubs in Human Functional Brain Networks. *Neuron* **79**, 798–813 (2013).
81. Tomasi, D. & Volkow, N. D. Association between functional connectivity hubs and brain networks. *Cereb. Cortex* **21**, 2003–2013 (2011).
82. Karahanoğlu, F. I. & Van De Ville, D. Transient brain activity disentangles fMRI resting-state dynamics in terms of spatially and temporally overlapping networks. *Nat. Commun.* **6**, 7751 (2015).
83. Seeley, W. W. *et al.* Dissociable Intrinsic Connectivity Networks for Salience Processing and Executive Control. *J. Neurosci.* **27**, 2349–2356 (2007).
84. Oni-Orisan, A. *et al.* Alterations in Cortical Sensorimotor Connectivity following Complete Cervical Spinal Cord Injury: A Prospective Resting-State fMRI Study. *PLoS One* **11**, e0150351 (2016).

Acknowledgements

We thank Dr. Marco Tettamanti for his essential technical support. This work was supported by EU FP7 INMIND Project (FP7-HEALTH-2013, grant agreement no. 278850), the CARIPO Funding 2014–0832 and the IVASCOMAR project “Identificazione, validazione e sviluppo commerciale di nuovi biomarcatori diagnostici prognostici per malattie complesse” (grant agreement no. CTN01_00177_165430).

Author Contributions

A.S. and S.P.C. performed analyses and wrote the manuscript. L.P. performed analyses. E.P., A.P., R.T., M.C., A.A., B.B. and A.P. performed clinical and neuropsychological assessment. B.P. performed [18F]FDG-PET imaging acquisitions. D.P. designed research, supervised the analyses and wrote the manuscript. All authors reviewed and approved the manuscript.

Additional Information

Competing Interests: The authors declare that they have no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2017